Hematology Reports, 2023 Paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired hematologic disorder, can be treated with C5 inhibitors (C5i) such as eculizumab or ravulizumab.
Jesse Fishman +4 more
doaj +1 more source
The inhibition of complement system in formal and emerging indications: results from parallel one-stage pairwise and network meta-analyses of clinical trials and real-life data studies [PDF]
, 2020 Producción CientíficaThis manuscript presents quantitative findings on the actual effectiveness of terminal complement component 5 (C5) inhibitors and complement component 1 (C1) esterase inhibitors through their formal and common “off-label ...
Adler, Marcel +14 more
core +1 more source
Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis [PDF]
, 2023 Background and purpose: Therapy for myasthenia gravis (MG) is undergoing a profound change, with new treatments being tested. These include complement inhibitors and neonatal Fc receptor (FcRn) blockers.
Espinosa, Pablo Ezequiel +4 more
core +1 more source
Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management [PDF]
, 2023 International audienceThis manuscript presents practical recommendations for managing acute attacks and implementing preventive immunotherapies for neuromyelitis optica spectrum disorders (NMOSD), a rare autoimmune disease that causes severe inflammation
Aktas, Orhan +139 more
core +1 more source
eJHaem, 2022 A 47‐year‐old male with paroxysmal nocturnal haemoglobinuria (PNH) controlled with routine ravulizumab administration suffered a massive haemolytic crisis due to choledocholithiasis.
Mitsuru Moriyama +6 more
doaj +1 more source
Swiss Survey on current practices and opinions on clinical constellations triggering the search for PNH clones. [PDF]
, 2023 UNLABELLED This national survey investigated the current practice in Switzerland by collecting participants' opinions on paroxysmal nocturnal hemoglobinuria (PNH) clone assessment and clinical practice.
Beauverd, Yan +14 more
core +2 more sources
Ravulizumab for the treatment of myasthenia gravis
Expert Opinion on Biological Therapy, 2023 Myasthenia gravis (MG) is a neurological B-cell mediated autoimmune disorder affecting the neuromuscular junction. MG therapeutics have always relied on nonselective immunosuppression with oral steroids and non-steroidal immunosuppressants, mainly with good clinical response.
Vanoli Fiammetta, Renato Mantegazza
openaire +3 more sources
Clinical Profile, Humanistic and Economic Burden of Paroxysmal Nocturnal Hemoglobinuria in Patients Treated With C5 Inhibitors. [PDF]
EJHaemABSTRACT Objectives To evaluate disease burden among paroxysmal nocturnal hemoglobinuria (PNH) patients prescribed C5 inhibitors (C5i). Methods Data were drawn from the Adelphi Real World PNH Disease Specific Programme, a cross‐sectional survey of physicians and PNH patients in Australia, Canada, France, Germany, Italy, Spain, the United Kingdom, and ...
Gandhi S +9 more
europepmc +2 more sources
Monoclonal antibodies in COVID-19 management: a scoping review [PDF]
, 2021 Coronavirus disease 2019 (COVID-19) was declared as pandemic on March 11th 2020 by the world health organization (WHO). Vaccination is for preventing COVID-19 morbidity but when people are infected, treatment is required and even after one and half years
Adaikkalavan, Umayal +3 more
core +2 more sources
PLoS ONE, 2020 BackgroundEculizumab has transformed management of paroxysmal nocturnal hemoglobinuria (PNH) since its approval. However, its biweekly dosing regimen remains a high treatment burden.
John Devin Peipert +19 more
doaj +1 more source